Blueprint Medicines (NASDAQ:BPMC) Posts Earnings Results, Misses Estimates By $0.11 EPS

Blueprint Medicines (NASDAQ:BPMC) posted its earnings results on Thursday. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11), Zacks reports. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Blueprint Medicines Stock Performance

BPMC stock opened at $94.35 on Friday. Blueprint Medicines has a fifty-two week low of $80.42 and a fifty-two week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a 50-day simple moving average of $99.56 and a 200 day simple moving average of $94.40.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the sale, the director now directly owns 157,557 shares of the company’s stock, valued at approximately $14,143,891.89. This represents a 8.69 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is owned by insiders.

Analysts Set New Price Targets

BPMC has been the subject of a number of research analyst reports. Piper Sandler lifted their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Wells Fargo & Company dropped their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.